Tian'an Pharmaceutical Co., Ltd.

As of December 31, 2007, Tian'an Pharmaceutical Co., Ltd. carries a market capitalization of 55.78M, placing it among publicly traded companies globally. Its enterprise value stands at 47.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2007, Tian'an Pharmaceutical Co., Ltd. has 13.94M shares outstanding.

As of December 31, 2007, Tian'an Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 17.81. The price-to-sales ratio is 5.26, and the price-to-book ratio stands at 3.87.

As of December 31, 2007, Tian'an Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 11.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Tian'an Pharmaceutical Co., Ltd. trades at an EV/FCF ratio of 18.65, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 47.65M versus a market cap of 55.78M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2007, Tian'an Pharmaceutical Co., Ltd. maintains a current ratio of 14.23, meaning it holds 14.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended December 31, 2007, Tian'an Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 25.31, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 25.89 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 23.75, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 25.11, useful for judging operating efficiency across full business cycles. Inventory turnover of 4.95 indicates how many times Tian'an Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2007, Tian'an Pharmaceutical Co., Ltd. recorded 556,096.00 in income tax expense. That works out to an effective tax rate of 15.03, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.70M, leaving 3.14M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 15, 2026, Tian'an Pharmaceutical Co., Ltd.'s stock has gained approximately 983.33% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.05.

Over the twelve months ended December 31, 2007, Tian'an Pharmaceutical Co., Ltd. generated 10.65M in revenue and converted that into 3.14M in net income, yielding earnings per share of 0.22. EBITDA reached 4.31M, while operating income came in at 3.81M.

These figures are as of December 31, 2007. Total book value stands at 14.43M, with working capital of 11.28M providing operational flexibility.

Tian'an Pharmaceutical Co., Ltd. produced 2.56M in operating cash flow over the twelve months ended December 31, 2007. After subtracting -6,642.00 in capital expenditures, free cash flow totaled 2.56M - equivalent to 0.18 per share.

Over the twelve months ended December 31, 2007, Tian'an Pharmaceutical Co., Ltd. posted a gross margin of 68.54, reflecting its pricing power and cost economics. The operating margin of 35.81 and net profit margin of 29.51 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2007. Free cash flow yield stands at 4.56, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tian'an Pharmaceutical Co., Ltd. shareholders.

As of December 31, 2007, Tian'an Pharmaceutical Co., Ltd. has an Altman Z-Score of 42.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.